777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com
Settore/i:
Settore:
Impiegati a tempo pieno: 13.450
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 7M | N/D | 1953 |
Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 6,59M | N/D | 1960 |
Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1,62M | 19,39M | 1959 |
Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1,95M | 45,28M | 1973 |
Ms. Marion E. McCourt | Executive Vice President of Commercial | 1,5M | 4,25M | 1960 |
Mr. Christopher R. Fenimore CPA | Senior VP of Finance & CFO | N/D | N/D | 1971 |
Ms. Patrice Gilooly | Senior Vice President of Quality Assurance & Operations | N/D | N/D | N/D |
Mr. Bob McCowan | Senior VP of IT & Chief Information Officer | N/D | N/D | N/D |
Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | N/D | N/D | N/D |
Mr. Joseph J. LaRosa | Executive VP, General Counsel & Secretary | 1,75M | 23,23M | 1959 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
L'ISS Governance QualityScore di Regeneron Pharmaceuticals, Inc. al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 9.